DFTX Definium Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:50
Jul 05
Jul 05
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector.
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector.
Risk: Small-cap biotech volatility; clinical trial outcomes binary; liquidity risk.
12:54
Jun 28
Jun 28
Speaker reacts to parent's DFTX position with surprise and a vague "early" comment, but does not state their own directional view or catalyst. No actionable thesis.
MED
18:46
Jun 24
Jun 24
The author celebrates a 420% gain since last year's post but provides no forward-looking direction or current position disclosure, only past performance.
LOW
20:05
Jun 22
Jun 22
Buy MNMD on the catalyst of RFK Jr. as Health Secretary, expecting favorable policy tailwinds for psychedelic treatments.
MED
20:05
Jun 22
Jun 22
Author endorses investing in psychedelic treatments under RFK Jr.'s appointment and highlights MNMD's massive gains from phase 3 results, signaling a forward-looking bullish catalyst.
18:17
Jun 22
Jun 22
Reports MNMD's phase 3 results and +50% price surge, no forward-looking directional commitment.
LOW
12:13
Jun 22
Jun 22
Premarket movers show hyperscalers declining while chip stocks rise, with notable gains in Apogee Therapeutics on an AbbVie acquisition and Getty Images soaring on an OpenAI partnership.
21:57
Jun 08
Jun 08
Author endorses psychedelic stocks as a good sector to be long with massive upside potential, but does not state a personal position in the specific tickers.
About DFTX Analyst Coverage
Buzzberg tracks DFTX (Definium Therapeutics, Inc.) across 5 sources. 1 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (12%). 8 total trade ideas tracked. Latest voices: Quoth the Raven, caesarcapitalz, Geiger_Capital.